Finally, a Blood Test for Alzheimer’s? In Clinical Use, Amyloid Scans Change Two-Thirds of Treatment Plans Searching for New AD Risk Variants? Move Beyond GWAS Monomeric Seeds and Oligomeric Clouds—Proteopathy News from AAIC Planning the First Primary ...
At AAIC, researchers debuted a method that detects changes in plasma Aβ42 in people with brain amyloid. If confirmed, a widely available screening test for presymptomatic AD could follow.
Gaps surrounding blood vessels in the brain may predict cognitive decline and vascular dementia.
The updated, expanded manual helps doctors diagnose this rare tauopathy and its variants earlier, in hopes that more patients can take advantage of clinical trials.
The prevalence of chronic traumatic encephalopathy supports a link between multiple concussions and this degenerative tauopathy, though the sample is self-selected.
An astrocytic Aβ protease, destabilization of γ-secretase by FAD mutations, and an sAPP receptor all made their debuts at Heidelberg conference.
Run-on repeats not only break DNA, they thwart the crucial repair pathways needed to sew the strands back together.
Knockout mice suggest opposing effects on lysosomal enzymes and neurodegeneration in frontotemporal dementia, implicating an ATPase.
Analysis of brain tissue from Alzheimer’s patients offers a glimpse of proteomic changes in the disease.
Researchers identified nuclear protein SRSF1 as the culprit that allows aberrant C9ORF72 RNA to escape into cytoplasm and give rise to toxic dipeptide repeat proteins.
Tau takes its place among the growing cadre of neurodegenerative disease proteins known to form liquid droplets. How the protein’s liquid form relates to its toxicity remains unclear.
Transcriptional profiling of human microglia sheds light on species differences, raising caution about translatability of rodent studies.
At a conference in Heidelberg, researchers proposed that Aβ oligomers trigger local translation of tau in cytosol and dendrites, and that targeting this aberrant tau may preserve synapses.
An antibody that activates Notch 3 signaling helps keep retinal blood vessels intact in a mouse model of the small vessel disease CADASIL.
A new prize seeks the ideal mix of factors to forecast who will progress to Alzheimer’s symptoms.